Related Experiment Video
Updated: Mar 6, 2026

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
Management of Hypertension Using Olmesartan Alone or in Combination
Xiaoshen Zhang1,2,3, Han Zhang1, Yuxia Ma4
1Department of Cardiology, Shanghai Tenth Hospital of Tongji University, Shanghai, 200072, China.
Insights
Olmesartan medoxomil effectively lowers and stabilizes blood pressure. Combining it with calcium channel blockers and diuretics improves blood pressure control and reduces adverse events in hypertensive patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertension is a major risk factor for cardiovascular diseases with increasing global prevalence.
- Lifestyle and genetic factors contribute significantly to hypertension incidence.
- Updated treatment standards are crucial due to high morbidity rates.
Purpose of the Study:
- To review the pharmacology, efficacy, and adverse events of olmesartan medoxomil.
- To evaluate olmesartan medoxomil as monotherapy and in combination with other antihypertensives.
Main Methods:
- Review of pharmacological data.
- Analysis of antihypertensive efficacy studies.
- Assessment of adverse event profiles.
Main Results:
- Olmesartan medoxomil demonstrates excellent efficacy in reducing and stabilizing blood pressure.
- Combination therapy with calcium channel blockers (CCBs) and diuretics enhances blood pressure control.
- Combined therapy also shows a reduction in adverse events.
Conclusions:
- Olmesartan medoxomil, an angiotensin II receptor blocker, is effective for blood pressure management.
- Combination therapy involving olmesartan medoxomil, CCBs, and diuretics offers superior blood pressure control and safety.
- Personalized and combination treatments are key in modern hypertension management.
Abstract:
Hypertension is one of the most significant and consistent risk factors for many cardiovascular diseases. The global prevalence of hypertension has dramatically increased over recent years. Life-style and genetic factors are generally considered to be primarily responsible for the incidence of hypertension. Concerning the high morbidity rate, setting up an updated standard for hypertensive patients becomes indispensable. According to the widely accepted standard treatments for hypertension, these four basic principles should be taken into account: low dosage; medication should provide long term-control; combination therapies are becoming common; personalized treatments are a newer approach. In most patients with hypertension, adequate control of BP can be achieved with combined therapy. Therefore, antihypertensive agents with complementary mechanisms are now recommended. In this review, we focus on the pharmacology, antihypertensive efficacy, and adverse events (AEs) of olmesartan medoxomil, either alone or in combination with other antihypertensive medications. In conclusion, olmesartan medoxomil, is an angiotensin II receptor blocker with an excellent efficacy in the reduction and stabilization of blood pressure. When combined with calcium channel blockers (CCBs) and diuretics, olmesartan medoxomil has a better effect on controlling BP and reducing AEs in patients.
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Hypertension V: Nursing Management
Heart Failure V: Medical Management

